Literature DB >> 27648154

Hypolactasia is associated with insulin resistance in nonalcoholic steatohepatitis.

Daniel Ferraz de Campos Mazo1, Rejane Mattar1, José Tadeu Stefano1, Joyce Matie Kinoshita da Silva-Etto1, Márcio Augusto Diniz1, Sebastião Mauro Bezerra Duarte1, Fabíola Rabelo1, Rodrigo Vieira Costa Lima1, Priscila Brizolla de Campos1, Flair José Carrilho1, Claudia P Oliveira1.   

Abstract

AIM: To assess lactase gene (LCT)-13910C>T polymorphisms in Brazilian non-alcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) patients in comparison with healthy controls.
METHODS: This was a transverse observational clinical study with NAFLD patients who were followed at the Hepatology Outpatient Unit of the Hospital das Clínicas, São Paulo, Brazil. The polymorphism of lactase non-persistence/lactase persistence (LCT-13910C>T) was examined by PCR-restriction fragment length polymorphism technique in 102 liver biopsy-proven NAFLD patients (steatosis in 9 and NASH in 93) and compared to those of 501 unrelated healthy volunteers. Anthropometric, clinical, biochemical and liver histology data were analyzed. Continuous variables were compared using the t or Mann-Whitney tests, and categorical data were compared with the Fisher's exact test. Univariate logistic regression and multivariate logistic regression adjusted for gender and age were performed.
RESULTS: No differences in the LCT-13910 genotype frequencies were noted between the NAFLD patients (66.67% of the patients with steatosis were CC, 33.33% were CT, and none were TT; 55.91% of the patients with NASH were CC, 39.78% were CT, and 4.3% were TT; P = 0.941) and the healthy controls (59.12% were CC, 35.67% were CT, and 5.21% were TT) or between the steatosis and NASH patients. That is, the distribution of the lactase non-persistence/lactase persistence polymorphism (LCT-13910C>T) in the patients with NAFLD was equal to that in the general population. In the NASH patients, the univariate analysis revealed that the lactase non-persistence (low lactase activity or hypolactasia) phenotype was associated with higher insulin levels (23.47 ± 15.94 μU/mL vs 15.8 ± 8.33 μU/mL, P = 0.027) and a higher frequency of insulin resistance (91.84% vs 72.22%, P = 0.02) compared with the lactase persistence phenotype. There were no associations between the LCT genotypes and diabetes (P = 0.651), dyslipidaemia (P = 0.328), hypertension (P = 0.507) or liver histology in these patients. Moreover, in the NASH patients, hypolactasia was an independent risk factor for insulin resistance even after adjusting for gender and age [OR = 5.0 (95%CI: 1.35-20; P = 0.017)].
CONCLUSION: The LCT-13910 genotype distribution in Brazilian NAFLD patients was the same as that of the general population, but hypolactasia increased the risk of insulin resistance in the NASH patients.

Entities:  

Keywords:  Genetic polymorphism; Insulin resistance; Lactose intolerance; Non-alcoholic fatty liver disease; Nonalcoholic steatohepatitis

Year:  2016        PMID: 27648154      PMCID: PMC5002498          DOI: 10.4254/wjh.v8.i24.1019

Source DB:  PubMed          Journal:  World J Hepatol


  61 in total

1.  A position statement on NAFLD/NASH based on the EASL 2009 special conference.

Authors:  Vlad Ratziu; Stefano Bellentani; Helena Cortez-Pinto; Chris Day; Giulio Marchesini
Journal:  J Hepatol       Date:  2010-05-07       Impact factor: 25.083

2.  Lactose digestion and the evolutionary genetics of lactase persistence.

Authors:  Catherine J E Ingram; Charlotte A Mulcare; Yuval Itan; Mark G Thomas; Dallas M Swallow
Journal:  Hum Genet       Date:  2008-11-26       Impact factor: 4.132

3.  Prevalence of lactase persistent/non-persistent genotypes and milk consumption in a young population in north-west Russia.

Authors:  Yulia Khabarova; Suvi-Tuulia Torniainen; Hanna-Anneli Nurmi; Irma-Elisabet Järvelä; Mauri-Kullervo Isokoski; Kari-Juhani Mattila Mattila
Journal:  World J Gastroenterol       Date:  2009-04-21       Impact factor: 5.742

4.  Changes in the prevalence of the most common causes of chronic liver diseases in the United States from 1988 to 2008.

Authors:  Zobair M Younossi; Maria Stepanova; Mariam Afendy; Yun Fang; Youssef Younossi; Hesham Mir; Manirath Srishord
Journal:  Clin Gastroenterol Hepatol       Date:  2011-03-25       Impact factor: 11.382

Review 5.  Milk, dairy products, and their functional effects in humans: a narrative review of recent evidence.

Authors:  Francesco Visioli; Andrea Strata
Journal:  Adv Nutr       Date:  2014-03-01       Impact factor: 8.701

6.  Adult-type hypolactasia and calcium intake in polycystic ovary syndrome.

Authors:  Elisabeth Lerchbaum; Albrecht Giuliani; Hans-Jürgen Gruber; Thomas R Pieber; Barbara Obermayer-Pietsch
Journal:  Clin Endocrinol (Oxf)       Date:  2012-12       Impact factor: 3.478

7.  Diets enriched in trans-11 vaccenic acid alleviate ectopic lipid accumulation in a rat model of NAFLD and metabolic syndrome.

Authors:  M Miriam Jacome-Sosa; Faye Borthwick; Rabban Mangat; Richard Uwiera; Martin J Reaney; Jianheng Shen; Ariel D Quiroga; René L Jacobs; Richard Lehner; Spencer D Proctor; Randal C Nelson
Journal:  J Nutr Biochem       Date:  2014-03-18       Impact factor: 6.048

8.  The T allele of a single-nucleotide polymorphism 13.9 kb upstream of the lactase gene (LCT) (C-13.9kbT) does not predict or cause the lactase-persistence phenotype in Africans.

Authors:  Charlotte A Mulcare; Michael E Weale; Abigail L Jones; Bruce Connell; David Zeitlyn; Ayele Tarekegn; Dallas M Swallow; Neil Bradman; Mark G Thomas
Journal:  Am J Hum Genet       Date:  2004-04-20       Impact factor: 11.025

9.  Dairy product intake is inversely associated with metabolic syndrome in Korean adults: Anseong and Ansan cohort of the Korean Genome and Epidemiology Study.

Authors:  Hyehyung Shin; Yeong Sook Yoon; Yoonna Lee; Cho-il Kim; Sang Woo Oh
Journal:  J Korean Med Sci       Date:  2013-09-25       Impact factor: 2.153

Review 10.  Steatosis and steatohepatitis: complex disorders.

Authors:  Kira Bettermann; Tabea Hohensee; Johannes Haybaeck
Journal:  Int J Mol Sci       Date:  2014-06-03       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.